[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.197.142.219. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 339
Citations 0
News From the Centers for Disease Control and Prevention
July 10, 2013

TB Drug Shortage Forces Control Programs To Make Onerous Choices

JAMA. 2013;310(2):135. doi:10.1001/jama.2013.7734

A national shortage of the first-line tuberculosis drug isoniazid has forced TB control programs to adopt strategies that could increase their costs, delay treatment, and miss opportunities to prevent latent infection from developing into active disease.

Isoniazid, along with rifampin, ethambutol, and pyrazinamide, form the core of first-line TB treatment regimens. An additional 6 drugs are approved as second-line treatments. Interruptions in the second-line drug supplies have been ongoing for several years, but the continuing isoniazid shortage that began in November 2012 is the first for a first-line TB drug. The shortage is attributed to manufacturers’ problems in getting the drug’s active ingredient and to 1 of 3 US isoniazid manufacturers having dropped out of the market until next year.

First Page Preview View Large
First page PDF preview
First page PDF preview
×